Par Health Launches Sugammadex Prefilled Syringe to Streamline Neuromuscular Blockade Reversal in Hospitals
Key Insights
Par Health (search) has launched a manufacturer-prepared, ready-to-use sugammadex injection in a 200 mg/2 mL prefilled syringe, with initial shipments already underway.
The new product expands the TruDelivery portfolio of premixed hospital pharmaceuticals, eliminating diluting, mixing, and compounding steps at the point of care.
Ready-to-use formulations may help hospitals reduce waste and costs, optimize workflow efficiency, and minimize the risk of preparation error.
Par Health (search), Inc. has announced the launch and initial shipments of its sugammadex injection in a manufacturer-prepared, ready-to-use 200 mg/2 mL prefilled syringe. The new product expands the company's TruDelivery portfolio of premixed hospital pharmaceuticals, which already includes Adrenalin, Bivalirudin, and Vasostrict.
Sugammadex is a specialized medication used during general anesthesia to reverse neuromuscular blockade caused by the muscle relaxants rocuronium and vecuronium. By delivering the drug in a prefilled syringe format, Par Health (search) aims to eliminate the diluting, mixing, and compounding steps traditionally required prior to patient administration.
Addressing Workflow Challenges in Healthcare Settings
"Healthcare providers are looking for solutions that improve workflow efficiency and reduce the risk of preparation error," said Dr. Bill Larkins, President, Sterile Injectables and Chief Scientific Officer at Par Health (search). "The addition of sugammadex injection to our TruDelivery portfolio underscores our focus on delivering ready-to-use solutions that address real-world challenges in healthcare settings."
Ready-to-use products are designed to streamline hospital operations by removing the need for product preparation or transfer at the point of care. According to the company, these solutions may help hospitals reduce waste and costs, optimize workflow efficiency, and minimize the risk of preparation error, enabling healthcare providers to focus on delivering quality patient care.
Expanding the TruDelivery Portfolio
The sugammadex prefilled syringe marks the latest expansion of Par Health (search)'s growing TruDelivery portfolio, further strengthening the company's ready-to-use injectable offerings enabled by its global contract manufacturing network. The RTU products also offer longer stability compared with standard compounded hospital mixtures.
Par Health (search), headquartered in St. Louis, is a global pharmaceutical company focused on developing, manufacturing, and delivering generic medicines, active pharmaceutical ingredients, and sterile injectable products across a broad range of therapeutic areas, dosage forms, and delivery technologies.